用于治疗 ALS 的基质金属蛋白酶-2/-9 抑制剂-猫眼课题宝

用于治疗 ALS 的基质金属蛋白酶-2/-9 抑制剂

批准号：

9763774

负责人：

IRVING SUCHOLEIKI

金额：

$45.76万

依托单位：

AQUILUS PHARMACEUTICALS, INC.

依托单位国家：

美国

项目类别：

财政年份：

2019

资助国家：

美国

项目状态：

已结题

起止时间：

2019-09-15 至 2021-01-31

来源：

https://reporter.nih.gov/project-details/9763774

关键词：

Address Amyotrophic Lateral Sclerosis Animal Model Applications Grants Award Behavioral Biochemical Biological Biological Availability Biological Markers Body Weight decreased CASP1 gene Chemicals Clinic Deterioration Devices Diagnosis Diagnostic Disease Disease Progression Disease model Dose Drug Kinetics FDA approved Female Gelatinase A Gelatinase B Goals Investigational New Drug Application Label Life Life Expectancy Measures Methodology Morphology Motor Neurons Mus National Institute of Neurological Disorders and Stroke Nervous system structure Neurodevelopmental Disorder Onset of illness Oral Penetration Pharmaceutical Preparations Pharmacologic Substance Phase Proteins Riluzole Rodent Model Rotarod Performance Test Running Small Business Innovation Research Grant Spinal Technology Testing Therapeutic Tissues Work animal efficacy diagnostic assay dosage efficacy study efficacy testing inhibitor/antagonist male mouse model nervous system disorder novel painful neuropathy pre-clinical research clinical testing response superoxide dismutase 1

项目摘要

项目成果

IRVING SUCHOLEIKI的其他基金

相似基金

相关文献

中文摘要

翻译

项目概要/摘要。Aquilus Pharmaceuticals，Inc.建议评估一个选择性，双重活性，基质金属蛋白酶-2（MMP-2）和MMP-9抑制剂，AQU-118，在肌萎缩侧索硬化症（ALS）超氧化物歧化酶-1（SOD-1）小鼠模型。的目标第一阶段是化学合成AQU-118，测定其在SOD-1中的口服药代动力学（PK），小鼠，然后通过剂量反应确定其在ALS的SOD-1小鼠模型中的功效。最后，A 然后进行组织形态学和免疫组织化学研究，以确定是否或与对照组相比，AQU-118的非口服给药导致脊髓组织内的任何生化变化控制。所提出的工作的最终目标是评估是否双重活性MMP-2/-9 抑制剂可用于治疗ALS。

英文摘要

Project Summary/Abstract. Aquilus Pharmaceuticals, Inc. proposes to evaluate the effects of a selective, dual active, matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitor, AQU-118, in the superoxide dismutase-1 (SOD-1) mouse model of amyotrophic lateral sclerosis (ALS). The goals for Phase I are to chemically synthesize AQU-118, determine its oral pharmacokinetics (PK) in SOD-1 mice and then determine its efficacy in the SOD-1 mouse model of ALS with dose response. Lastly, a tissue morphology & immunohistochemical study will then be performed to determine whether or not oral dosing with AQU-118 results in any biochemical changes within spinal tissues as compared to controls. The ultimate goal of the proposed work is to evaluate whether a dual active MMP-2/-9 inhibitor can be used to treat ALS.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文